biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain

BIOASIS TECHNOLOGIES INC. (TSX VENTURE:BTI)(OTCQX:BIOAF), a pioneering
biopharmaceutical company focused on overcoming the limitations of therapeutic
drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014,
that its newly discovered carrier peptide-Transcendpep-effectively delivered
siRNA across the BBB and into brain cells. The company announces that it has
achieved effective knock-down of the expression of a target gene in the brain in
a sequence-specific manner. Independent analysis of brain tissue revealed that,
not only did Transcendpep deliver the siRNA to the brain tissue, but it also
reduced the expression of the target gene by 40% to 50% after a single dose. 


"Injection of a small bioconjugate of siRNA coupled to Transcendpep achieved a
significant reduction in target gene expression in the brain," says Dr. Wilfred
Jefferies, Founding Scientist of biOasis. "This represents a potential
advancement for reducing disease-associated gene expression that often leads to
the pathology present in a variety of brain diseases." 


"These findings expand the preeminent standing of biOasis in the area of BBB
carriers and provides vast opportunities for Transcendpep to act as a platform
to significantly advance the treatment of brain diseases," says Rob Hutchison,
CEO. "Due to the vast market potential of siRNA delivery to the brain, we are
focused on advancing this program to the IND stage and commencing Phase I
Clinical Trials as soon as possible. This adds to biOasis' development programs
in the delivery of therapeutics across the BBB, which includes our metabolic
disease programs for lysosomal storage diseases such as Hunter Syndrome and
Sandhoff Disease and our oncology program (Transcendpep-Herceptin(C)) for the
treatment of brain metastases of HER2+ breast cancer. In addition to the
aforementioned programs, we continue to further our partnership with MedImmune
and develop relationships with other pharmaceutical companies." 


About Transcend & Transcendpep

Transcend and Transcendpep are biOasis' proprietary platform for the delivery of
therapeutics across the BBB to address unmet medical needs in the treatment of
metastatic brain cancers as well as neurodegenerative and metabolic diseases.
The BBB represents the single greatest challenge in treating neurological
disorders. The ability to effectively permeate the BBB offers the opportunity
for clinically approved drugs nearing the end of their patent life, extending
their intellectual property. 


About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada focused on overcoming the limitations of therapeutic drug
delivery across the BBB. The company is developing and commercializing a
proprietary brain delivery technology to address unmet medical needs in the
treatment of central nervous system disorders. biOasis trades on the OTCQX under
the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For
more information about the company please visit www.bioasis.ca.


Forward-Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not succeed in
preclinical or clinical trials, or future products in our targeted corporate
objectives; our future operating results are uncertain and likely to fluctuate;
we may not be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching our products
may be greater than anticipated; we have no experience in commercial
manufacturing; we may face unknown risks related to intellectual property
matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given these risks
and uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements and
information made herein are based on our current expectations and we undertake
no obligation to revise or update such forward- looking statements and
information to reflect subsequent events or circumstances, except as required by
law.


On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO 

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Tiffany Tolmie
Company Contact
778-383-3280 x103
tiffany@bioasis.ca
www.bioasis.ca


Gale Capital
Investor Relations Contact
604-200-1480
info@galecapital.com
BiOasis Technologies (TSXV:BTI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024